공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 파이프라인 리뷰

Methionine Aminopeptidase 2 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 364842
페이지 정보 영문 62 Pages
가격
US $ 3,500 ₩ 4,009,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,018,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,027,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 파이프라인 리뷰 Methionine Aminopeptidase 2 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 62 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

메티오닌 아미노펩티디아제 2(EC 3.4.11.18)를 표적으로 한 치료제 개발 상황에 대해 분석했으며, 개발 단계, 약제 표적, 작용기서, 투여 경로 및 분자 종류별 분석, 치료제 개발에 참여하고 있는 기업 개요, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) 개요

치료제 개발

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 개발중인 제품 - 개발 단계별

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 개발중인 제품 - 치료 분야별

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 개발중인 제품 - 적응증별

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 파이프라인 제품 개요

  • 초기 단계 제품

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 기업에서 개발중인 제품

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 대학/기관에서 개발중인 제품

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 치료제 평가

  • 단독요법/병용요법 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) 치료제 개발에 참여하고 있는 기업

  • Chong Kun Dang Pharmaceutical Corp.
  • SynDevRx, Inc.
  • Takeda Pharmaceutical Company Limited
  • Zafgen Inc.

약제 개요

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 휴지중인 프로젝트

메티오닌 아미노펩티디아제 2(EC 3.4.11.18) : 주요 뉴스와 프레스 릴리스

부록

KSM 16.08.10

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Pipeline by Merck KGaA, H2 2019
  • Pipeline by Primetime Life Sciences LLC, H2 2019
  • Pipeline by SynDevRx Inc, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Zafgen Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 11 molecules.

Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity.

The report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Gastrointestinal, Genetic Disorders and Infectious Disease which include indications Obesity, Non-Alcoholic Steatohepatitis (NASH), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Solid Tumor, Giardiasis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Prader-Willi Syndrome (PWS) and Type 2 Diabetes.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
  • The report reviews Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development
  • Asieris Pharmaceuticals Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Merck KGaA
  • Primetime Life Sciences LLC
  • SynDevRx Inc
  • Takeda Pharmaceutical Co Ltd
  • Zafgen Inc
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles
  • APL-1301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • beloranib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fumagillin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-8891 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitroxoline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLS-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SDX-7195 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SDX-7320 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZGN-1061 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZGN-1345 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 24, 2019: Zafgen announces agreement With U.S. Food And Drug Administration on new nonclinical study design for ZGN-1061
  • Jun 26, 2019: Asieris concludes enrolment for Phase Ib trial of APL-1202
  • Jun 10, 2019: Zafgen presented full results of Phase 2 clinical trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
  • May 30, 2019: Zafgen announces regulatory update on ZGN-1061
  • Jan 17, 2019: Zafgen announces positive results for second cohort of phase 2 clinical trial of ZGN-1061
  • Nov 26, 2018: Zafgen provides update on investigational new drug application for ZGN-1061
  • Nov 01, 2018: Asieris announced appointment of Dr. Gail Brown as acting Chief Medical Officer
  • Jun 25, 2018: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
  • Jun 23, 2018: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
  • May 30, 2018: Asieris Awarded Best Poster at AUA 2018 Annual Meeting
  • Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
  • Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061
  • Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
  • Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
  • Aug 24, 2017: Asieris Pharmaceuticals Invited to Present at the 20th Annual Meeting of CSCO
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q